Sir, I read with great interest the review article on Lhermitte's sign by Khare and Seth. [1] The sign occurs, inter alia, in multiple sclerosis, in traumatic lesions of the cervical cord, and in subacute combined degeneration. I agree that very few studies are available on Lhermitte's sign and there is need of more research in this particular field. In this current review, treatment with extracranial picotesla range pulsed electromagnetic fields was said to be effective. Neck brace and collar might also be prescribed by physical therapists, and exercises and relaxation technique were claimed to be helpful.
I found that carbamazepine in a rather small dosage had an immediate symptomatic effect on the paresthesiae associated with Lhermitte's sign in three patients with multiple sclerosis. [2] In two of the patients, the symptoms reappeared when the treatment was discontinued. In two cases, the effect of the drug could be reproduced in several short series of treatment and was checked at each examination by letting the patient repeatedly bend his/her head forward in both a recumbent and sitting position. The therapeutic results in my cases resembled those obtained by carbamazepine in connection with the treatment of trigeminal neuralgia and spontaneous paroxysmal symptoms in multiple sclerosis such as painful tonic seizures and paroxysmal dysarthria.
Bupropion and Iron for Restless Leg Syndrome: Do They Have
Efficacy Similar to Ropinirole?
Sir, I read with interest the study on efficacy and tolerability of ropinirole, bupropion, and iron for the treatment of restless leg syndrome (RLS) reported by Vishwakarma et al. [1] in October-December issue of 2016. The authors have rightly pointed out that the dopamine agonist, ropinirole is considered as the standard treatment of idiopathic RLS (beside pramipexole and rotigotine), at a dose ranging from 1.5 to 4.6 mg in the systematic review and meta-analysis by Aurora et al. [2] Similar conclusions were reached in the meta-analysis by Scholz et al. [3] There is only one randomized, placebo-controlled trial [4] that found bupropion to be efficacious than placebo in RLS at 3 weeks but not at 6 weeks. Although iron therapy has been evaluated in six randomized-controlled trials, the meta-analysis by Trotti et al. [5] found that the evidence is not sufficient to conclude that it is beneficial in RLS. In the current study, the authors have compared fixed-dose bupropion and combination of iron with folic acid, with ropinirole, which is the standard treatment available and acts as an active control. However, the authors have not specified whether this is a superiority or a noninferiority trial; the latter can be conducted with smaller sample sizes. [6] The authors have recruited 103 patients but presented the data for 90 patients. It is not clear whether the 13 dropouts received treatment and did not complete 6-week follow-up and at which stage they were lost. A CONSORT diagram depicting the flow of participants in the study is desirable, which improves the understanding of the results. [7] Furthermore, in addition to completer analysis, an intention-to-treat analysis including all randomized patients would reduce the bias in reporting results. [8] Furthermore, from the description, it is not clear about the process of randomization and the allocation concealment. [9] For the primary outcome, i.e., International Restless Legs Scale (IRLS) score, there were significant effect of time, which suggests improvement in all the three groups, and significant group × time interaction, suggesting differences in efficacy between the treatment groups. Post hoc comparison suggested ropinirole be more effective than bupropion and iron and folate combination as shown in Figure 1 of Vishwakarma et al. [1] However, in the absence of control group, it was assumed that both bupropion and iron and folate combination were effective treatment in RLS. In reality, both treatment groups were neither superior nor equivalent to ropinirole, which is considered as standard treatment. In such situations, it is better to report the effect sizes of the differences with 95% confidence intervals and discuss the practical significance of the finding, i.e., reduction in IRLS scores. Furthermore, it was interesting to observe that ropinirole was effective at a dose of 0.5 mg/day, which is much lower than the recommended dose of 1.5-4.6 mg/day.
Response to Reader's Queries
Sir, We are thankful to the reader for his interest in our paper and for the concerns raised. This was a noninferiority trial where we wanted to analyze whether the bupropion and iron-folate were as efficacious as ropinirole in the short-term treatment of Willis-Ekbom disease/Restless legs syndrome (WED/RLS). The consort diagram is provided with this letter [ Figure 1 ]. As already mentioned, random allocation was done using a list of random numbers, and this has been reported to be an effective method. [1] Author who was responsible of measuring the improvement was blinded of the group allocation that removes the observer's bias. We agree with the statement mentioned that "both groups were neither superior nor equivalent to the ropinirole," and we have already mentioned it in the paper "Pair-wise comparison depicted that ropinirole group differed from other two groups in International RLS Severity Rating (IRLS) score (F = 7.06; P = 0.001), which were comparable to each other" [ Table 1 ]. [2] As pointed out by the reader, in the absence of placebo control group, it cannot be commented whether bupropion or iron-folate combination was better than placebo. Placebo group could not be included because of restrictions from the regulatory bodies. [3] However, it must be noted that placebo is not an inert substance and this has been found effective in a number of disorders including WED/RLS. [4, 5] In this study, mixed ANOVA was used, and in this statistical method, effect size was depicted using partial eta square. In this study, partial eta square value was
